• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by IO Biotech Inc.

    4/7/25 4:07:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    S-8 1 d849886ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on April 7, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IO BIOTECH, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   87-0909276

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Ole Maaløes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (Address of principal executive offices)

    IO BIOTECH, INC. 2021 EQUITY AND INCENTIVE PLAN

    (Full title of the plan)

    Corporation Trust Company

    Corporation Trust Center

    1209 N Orange Street

    Wilmington, DE 19801

    (800) 677-3394

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement is being filed by IO Biotech, Inc. (the “Registrant”) for the purpose of registering an additional 2,635,236 shares of the Registrant’s Common Stock, par value $0.001 per share (the “Common Stock”), that were reserved for issuance under the IO Biotech, Inc. 2021 Equity and Incentive Plan. This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registrant’s prior Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March 11, 2024 (SEC File No.  333-277826), February 6, 2023 (SEC File. No.  333-269597), and February 8, 2022 (SEC File No. 333-262587) (collectively, the “Prior Registration Statements”). This Registration Statement relates to securities of the same class as those to which the prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General E of Form S-8, the contents of the Prior Registration Statements, are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). Documents containing the information required by Part I of the Registration Statement will be sent or given to plan participants as specified by Rule 428(b)(1) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by the Registrant are incorporated in this Registration Statement by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

     

      (1)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025;

     

      (2)

    The description of the Common Stock included in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on November 2, 2021, including any subsequent amendments or reports filed to update such description.

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).

    Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits

     

    Exhibit
    Number

      

    Description

    4.1    Amended and Restated Certificate of Incorporation of IO Biotech, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form 10-Q (Registration No. 001-41008), filed with the Commission on August 11, 2023).
    4.2    Amended and Restated Bylaws of IO Biotech, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed (Registration No. 001-41008), filed with the Commission on December 16, 2024).
    4.3    IO Biotech, Inc. 2021 Equity and Incentive Plan (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form S-8 (Registration No. 333-269597), filed with the Commission on February 6, 2023).
    5.1*    Opinion of Sidley Austin LLP with respect to the validity of the securities being registered hereby.
    23.1*    Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm.
    23.2*    Consent of Sidley Austin LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on the signature page of this Registration Statement).
    107*    Filing Fee Table

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Copenhagen, Denmark, on the 7th day of April, 2025.

     

    IO Biotech, Inc.
    By:  

    /s/ Mai-Britt Zocca

      Mai-Britt Zocca, Ph.D.
      Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    Each of the undersigned officers and directors of IO Biotech, Inc. does hereby severally constitute and appoint Mai-Britt Zocca and Amy Sullivan, and each of them acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE    TITLE    DATE

    /s/ Mai-Britt Zocca

       Chief Executive Officer and Director    April 7, 2025
    Mai-Britt Zocca, Ph.D.    (Principal Executive Officer)   

    /s/ Amy Sullivan

       Chief Financial Officer    April 7, 2025
    Amy Sullivan, M.B.A.    (Principal Financial Officer)   

    /s/ Brian Burkavage

       Chief Accounting Officer & Vice President of Finance    April 7, 2025
    Brian Burkavage    (Principal Accounting Officer)   

    /s/ Peter Hirth

       Chairman of the Board    April 7, 2025
    Peter Hirth, Ph.D.      

    /s/ Helen Collins

       Director    April 7, 2025
    Helen Collins, M.D.      

    /s/ Christian Elling

       Director    April 7, 2025
    Christian Elling, Ph.D.      

    /s/ Kathleen Sereda Glaub

       Director    April 7, 2025
    Kathleen Sereda Glaub, M.B.A.      

    /s/ Heidi Hunter

       Director    April 7, 2025
    Heidi Hunter      

    /s/ David V. Smith

       Director    April 7, 2025
    David V. Smith, M.B.A.      
    Get the next $IOBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    9/30/2025Buy → Hold
    TD Cowen
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IO Biotech Provides Corporate Update

    Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic al

    1/30/26 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Exploration of Strategic Alternatives

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution. The company is also evaluating a further reduction-in-force and other efforts to significantly reduce the company's operating expenses while the company explores a range of strategic alternative

    1/21/26 5:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

    Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both

    12/15/25 4:05:00 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded IO Biotech from Equal-Weight to Underweight and set a new price target of $0.36

    1/8/26 8:40:06 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by TD Cowen

    TD Cowen downgraded IO Biotech from Buy to Hold

    9/30/25 8:32:59 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith David V

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:46 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunter Heidi

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:20 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirth Peter

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:26:55 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by IO Biotech Inc.

    SCHEDULE 13G - IO Biotech, Inc. (0001865494) (Subject)

    2/6/26 4:10:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IO Biotech Inc.

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    1/30/26 4:53:41 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.

    SCHEDULE 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    1/23/26 7:05:19 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hunter Heidi bought $20,884 worth of shares (15,000 units at $1.39) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/2/25 7:53:36 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/26/24 8:50:34 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/23/24 6:56:14 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    View All

    IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

    -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

    1/9/25 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

    NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

    4/15/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

    NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

    4/5/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Financials

    Live finance-specific insights

    View All

    IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

    Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont

    8/11/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

    NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast/conference call

    8/10/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

    Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

    3/14/23 4:11:47 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    11/13/24 5:30:28 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

    SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    9/17/24 9:01:25 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    5/14/24 9:35:27 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care